ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125 Only Relapse

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00926107
Recruitment Status : Terminated (The study ended prematurely due to the low accrual rate (24% of the expected accrual rate) in the first two years of patients enrolment)
First Posted : June 23, 2009
Last Update Posted : November 10, 2011
Sponsor:
Information provided by (Responsible Party):
Hellenic Cooperative Oncology Group

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Terminated
  Actual Primary Completion Date : October 2011
  Actual Study Completion Date : October 2011